Literature DB >> 11030536

Outpatient ureteroscopic lithotripsy: selective internal stenting and factors enhancing success.

M C Cheung1, S K Yip, F C Lee, P C Tam.   

Abstract

PURPOSE: To evaluate a policy of selective, short-duration internal stenting after outpatient ureteroscopic laser lithotripsy. PATIENTS AND METHODS: From January 1997 to April 1998, 62 patients (34 male, 28 female) with a mean age of 50 (range 21-80) years underwent outpatient ureteroscopic lithotripsy using a holmium laser (365 microm; 0.5-1.4J/5-10 Hz) and 6F/7.5F semirigid ureteroscope. Internal stents were inserted selectively in patients with severe preoperative obstruction (intravenous urogram finding), tight stone impaction (endoscopic finding), or significant residual obstruction (on-table retrograde pyelogram finding) despite stone clearance. Patient demographics, stone measures, stone clearance rates, complications, postoperative pain scores, analgesic requirement, and follow-up imaging were compared for the stented and unstented patients.
RESULTS: With the present criteria of selective internal stenting, stents were inserted in 56% of the patients for a mean duration of 3.6 weeks. Excluding those patients with residual stones requiring further interventions, the stenting rate was 39% with a mean duration of 1.9 weeks. There was no difference in patient characteristics, stone burden, and stone levels between the stented and unstented group. The mean operating time for the unstented group was shorter than for the stented group (45.6 minutes v 56.6 minutes; P = 0.03). The stone clearance rates were similar for the two groups (96% v 97%), but the complication rate of the stented group was higher (8.6% v 3.7%). The mean postoperative pain score and analgesic requirement were similar in the two groups on postoperative day 1 but significantly less in the unstented group on day 3.
CONCLUSIONS: The criteria for selective internal stenting are useful in determining when a stent should be used. By omitting the stent insertion in the absence of these criteria, operating time, postoperative pain, and analgesic requirement were reduced without increasing the complication rate. Ureteral stricturing was absent despite the low stenting rate.

Entities:  

Mesh:

Year:  2000        PMID: 11030536     DOI: 10.1089/08927790050152140

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  7 in total

1.  [The frequency-doubled double-pulse Neodym:YAG laser lithotripter (FREDDY) in lithotripsy of urinary stones. First clinical experience].

Authors:  A Ebert; J Stangl; R Kühn; W Schafhauser
Journal:  Urologe A       Date:  2003-03-05       Impact factor: 0.639

Review 2.  Preoperative double-J stent placement can improve the stone-free rate for patients undergoing ureteroscopic lithotripsy: a systematic review and meta-analysis.

Authors:  Yubo Yang; Yin Tang; Yunjin Bai; Xiaoming Wang; Dechao Feng; Ping Han
Journal:  Urolithiasis       Date:  2017-11-01       Impact factor: 3.436

3.  The role of stenting in relieving loin pain following ureteroscopic stone therapy for persisting renal colic with hydronephrosis.

Authors:  Mahmoud Mustafa
Journal:  Int Urol Nephrol       Date:  2007       Impact factor: 2.370

4.  [Ureteroscopy under intravenous analgesia with remifentanil].

Authors:  P-H Langen; M Karypiadou; J Steffens
Journal:  Urologe A       Date:  2004-06       Impact factor: 0.639

5.  Successful treatment of stent knot in the proximal ureter using ureteroscopy and holmium laser.

Authors:  Masters M Richards; Daniel Khalil; Ayman Mahdy
Journal:  Case Rep Med       Date:  2011-05-10

6.  Effect of single-dose dexmedetomidine on postoperative recovery after ambulatory ureteroscopy and ureteric stenting: a double blind randomized controlled study.

Authors:  I I Shariffuddin; W H Teoh; S Wahab; C Y Wang
Journal:  BMC Anesthesiol       Date:  2018-01-05       Impact factor: 2.217

7.  Flexible and rigid ureteroscopy in outpatient surgery.

Authors:  Abeni Oitchayomi; Arnaud Doerfler; Sophie Le Gal; Charles Chawhan; Xavier Tillou
Journal:  BMC Urol       Date:  2016-01-28       Impact factor: 2.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.